Swiss biotech company Actelion (ATLN.S) said on Thursday it had agreed to be purchased by Johnson & Johnson (JNJ.N) in a $30 billion deal.
The all-cash offer, to acquire all of the outstanding shares of Actelion for $280 per share, payable in U.S. dollars, was unanimously approved by the Boards of Directors of both companies, Actelion and Johnson & Johnson said in a joint statement.
The Middle East Observer is a leading online platform dedicated to providing unbiased, in-depth coverage of the Middle East, North Africa and the world. Our expert team of journalists delivers timely news and analysis across a diverse range of topics, including politics, economics, life style, science, and technology. We strive to inform and engage our readers with informative, premium coverage, and thought-provoking content.
Copyright © MEO. All Rights Reserved.
